EMA Explains How To Make Risk Minimization Measures Robust & Effective

Pharmacovigilance experts speaking at an event organized by the European Medicines Agency discussed the rationale behind revised requirements relating to how drug sponsors must develop and evaluate risk minimization measures and thereby improve the safety of their medicines.

Hands of general practitioner filling paper medical records. Doctor in white coat doing paperwork at workplace with laptop, writing notes, preparing documents, reports, prescription. Close up
Patient and doctor representatives can contribute to user-testing of risk minimization materials • Source: Shutterstock

The European Medicines Agency’s updated guideline on risk minimization and the measures drug sponsors should take to ensure their products are used safely places greater emphasis throughout on the need to involve health care professionals and patient representatives in designing, testing, disseminating and evaluating the effectiveness of such measures.

Key Takeaways
  • The European Medicines Agency held a webinar to discuss its revised guideline on risk minimization measures (RMMs) and the related addendum on evaluating RMMs.

While most risks for drug products can be sufficiently managed by routine risk minimization measures (eg, summary of product characteristics,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three

 

The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.

Lilly Wins EU Thumbs Up For Kisunla After EMA Reverses Rejection

 

The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.

EMA Says ‘No’ To Roche/Sarepta’s DMD Gene Therapy Elevidys

 

The European Medicines Agency has recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy, despite the product securing approvals in the US and other markets.

EU’s Life Sciences Strategy Faces Race Against Time, Says Clinical Trials Community

 
• By 

The report gave examples of missed opportunities for innovation and patient access, as well as regulatory and operational problems that undermine the conduct of timely clinical trials in Europe.

More from Agency Leadership

US FDA Commissioner Makary Is Learning To Appreciate His Staff

 

After three months on the job, FDA Commissioner Martin Makary is sounding much more effusive about the quality of the agency staff. Better late than never?

Complete Response Letter Trio Raises Prospect Of Tidal Shift In Regenerative Medicine Regulation

 

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

Business Background Of New CDER Director George Tidmarsh

 

George Tidmarsh has extensive experience in the biopharmaceutical industry and led several drugs to FDA approval.